EWP
NVCR icon

Elevation Wealth Partners’s NovoCure NVCR Stock Holding History

Elevation Wealth Partners’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.85K Buy
584
+473
+426% +$7.16K ﹤0.01% 845
2026
Q1 		$1.21K Sell
111
-106
-49% -$1.32K ﹤0.01% 977
2025
Q4 		$2.81K Buy
217
+55
+34% +$706 ﹤0.01% 741
2025
Q3 		$2.09K Buy
+162
New +$2.16K ﹤0.01% 638

Other funds holding NVCR

BC
Burney Company Reston, Virginia $3.71B AUM 37.66% 1-Year Est. Return
CMF
Counterpoint Mutual Funds San Diego, California $1.01B AUM 37.65% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
CG
Caprock Group Boise, Idaho $5.22B AUM 42.47% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

Elevation Wealth Partners's NVCR Position: Q2 2026 in Review

Elevation Wealth Partners increased its NovoCure (NVCR) stake by 426% in Q2 2026, buying an estimated $7.16K and bringing the position to 584 shares worth $8.85K. The position accounts for ﹤0.01% of the portfolio, ranked #845.

Elevation Wealth Partners first reported a position in NVCR in Q3 2025 and has held it in 4 quarters since. 37 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

  • Elevation Wealth Partners held 584 shares of NovoCure worth $8.85K as of Q2 2026.
  • Elevation Wealth Partners bought 473 NovoCure shares in Q2 2026, an estimated $7.16K.
  • NovoCure made up ﹤0.01% of Elevation Wealth Partners's portfolio in Q2 2026, its #845 holding.
  • Elevation Wealth Partners first reported a position in NovoCure in Q3 2025 and has held it in 4 quarters since.
  • 37 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on Elevation Wealth Partners's 13F filing for Q2 2026, filed 8 Jul 2026.